Drug Approval | December 23, 2023
Zydus Lifesciences' API site in Ahmedabad. receives 6 observations from USFDA
This PAI-cum-GMP USFDA inspection was conducted from December 14 to December 22, 2023
This PAI-cum-GMP USFDA inspection was conducted from December 14 to December 22, 2023
Atlas Life Sciences (India) has successfully commenced the commercial production of API - Intermediate at its new plant at Chhatral,
The findings of Phase 3 study are in line with Phase 2 study conducted in the US and Europe
First published clinical trial using live biotherapeutic candidate in Covid-19 patients suggests role in improving outcomes
Blenrep (belantamab mafodotin) plus BorDex showed statistically significant progression-free survival (PFS) benefit versus daratumumab plus BorDex
Gene therapy AB-1005 being developed to locally increase glial cell line-derived neurotrophic factor (GDNF) levels
This approval showcases Teva’s proven strengths in complex generic formulations development and device engineering
Solara Active Pharma Sciences has reported total income of Rs. 426.42 crores during the period ended September 30, 2023
Likmez oral suspension is the first and only FDA-approved liquid option for patients with adherence hurdles such as dysphagia, difficulty swallowing
Total transaction value of the divestment is Rs. 3,660 million
Subscribe To Our Newsletter & Stay Updated
